|
|
Vaccine Detail
|
MUC1-Tn(T9,S15,T16)-Pam3CSK4-P30 Trivalent/Monovalent Vaccine |
| Vaccine Information |
- Vaccine Name: MUC1-Tn(T9,S15,T16)-Pam3CSK4-P30 Trivalent/Monovalent Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 VNTR (HGVTSAPDTRPAPGSTAPPA), Tn at T9, S15, T16 (Zhou et al., 2024)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic self-adjuvanted three-component vaccine comprising the TLR2 agonist Pam3CSK4, the T-helper epitope P30 (TT947-967: FNNFTVSFWLRVPKVSASHLE) from tetanus toxoid, and the MUC1 tandem repeat glycopeptide (HGVTSAPDTRPAPGSTAPPA) bearing Tn antigens at T9, S15, and T16, assembled via click chemistry with 6-aminohexanoic acid flexible spacers. Two formulations were developed: monovalent (MW ~7043 Da) and trivalent (MW ~12964 Da), carrying one and three MUC1 glycopeptide chains respectively on a single lipopeptide scaffold, with no significant biocompatibility threats upon repeat injection. In WT mice, both vaccines elicited robust mixed Th1/Th2 IgG responses (predominant IgG2b, IgG1, IgG3, with increases in IgG2a and IgM), with monovalent producing moderately higher total IgG titers. In MUC1-Tg mice, the trivalent showed a more Th2-biased profile (IgG1>IgG2a, IgG3, IgM), suggesting more MUC1 glycopeptide-specific responses. Flow cytometry confirmed specific antisera binding to B16-MUC1 cells but not MUC1-negative HEK293T controls. Despite lower antibody titers, the trivalent achieved superior antitumor efficacy in both models: in WT mice, both vaccines delayed tumor growth and prolonged survival (p<0.05), with 3/5 trivalent-group mice surviving beyond 40 days, one showing complete tumor rejection, and all three resisting rechallenge on day 71; in MUC1-Tg mice, the trivalent significantly delayed tumor growth (p<0.01) and combined with anti-PD-1 blockade significantly improved survival (p<0.01) (Zhou et al., 2024).
|
| Host Response |
|
|
| References |
Zhou et al., 2024: Zhou Y, Li X, Guo Y, Wu Y, Yin L, Tu L, Hong S, Cai H, Ding F. Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy. MedComm. 2024; 5(2); e484. [PubMed: 38344400].
|
|
